Company intelligence / Profile preview
Hisun Bio Pharmaceutical
Taizhou, Zhejiang, Chinahisunpharm.com ↗
- Ownership
- Private
- Employees
- ~7000
- Development stage
- Commercial
01
Overview
Hisun Bio Pharmaceutical, a division of Zhejiang Hisun Pharmaceutical, has a robust commercial portfolio of biosimilars and biologics approved in China, including adalimumab, etanercept, infliximab, tocilizumab, trastuzumab. The company also develops innovative drugs and small molecules with multiple programs in clinical development targeting oncology and metabolic diseases.
- Therapeutic areas
- OncologyEndocrinologyImmunologyDermatologyRheumatologyGastroenterology
- Modalities
- Monoclonal antibodyBiosimilarFusion proteinRecombinant proteinPeptidesVaccine (biologic)Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Former joint venture with Pfizer (Hisun-Pfizer Pharmaceuticals)ongoing collaborations with Nanjing Normal University for synthetic biology R&D
Beyond the preview
Go deeper on Hisun Bio Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hisun Bio Pharmaceutical.